Just a few months into a new launch in chronic inflammatory demyelinating polyneuropathy (CIDP), agrenx’s Vyvgart is already making headway in the rare disease space, just one of the long-term growth ...

A blockbuster Argenx therapy now has an additional FDA approval as a treatment for a rare autoimmune disorder affecting nerves, marking the first new treatment for this condition in decades and a new ...

As many as four percent of the world’s population lives with an autoimmune disease, in which the immune system fails to distinguish between ‘self’ and ‘non-self’ and mistakenly attacks the body, ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a challenge to diagnose even for the most experienced doctors. A major reason: It’s a rare disorder, so not many have seen it. But many ...

An inability to distinguish between CIDP and POEMS syndrome can negatively affect treatment strategies and outcomes. A 2-step protocol using conduction block and maximum/minimum cross-sectional area ...

CIDP is a treatable condition that affects the peripheral nervous system. IVIG, plasma exchange, and corticosteroid therapy are the first-line treatment options, but a newer medication for adults has ...

Investing.com - Argenx (NASDAQ:ARGX) stock soared premarket Monday after the Dutch biotech’s Vyvgart Hytrulo shot gained U.S. approval to treat a rare nervous system disorder. The drug received gained ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disease that damages and destroys the nerves in a person’s body. CIDP affects a person’s ability to move, especially ...

CEO Tim Van Hauwermeiren emphasized 2024 as a "phenomenal year," highlighted by expanding the reach of VYVGART to over 10,000 patients globally across three approved indications. He noted the ...

From its initial nod in generalized myasthenia gravis (gMG) in 2021 to a subcutaneous approval this summer—and now, a stellar showing in a second neuromuscular disease—Argenx’s flagship drug Vyvgart ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) may be a rare disease, but it is one of the most common forms of neuropathy and the most common form of chronic autoimmune neuropathy. Roughly ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a serious condition, but it’s treatable. The earlier you’re diagnosed and the earlier you start treatments, the better the chance you’ll ...